0IJO Stock Chart & Stats
$44.87
$0.29(0.84%)
At close: 4:00 PM EST
$44.87
$0.29(0.84%)
Day’s Range― - ―
52-Week Range$33.81 - $57.49
Previous CloseN/A
Volume2.15K
Average Volume (3M)2.21K
Market Cap
$13.92B
Enterprise Value$11.12K
Total Cash (Recent Filing)$777.21M
Total Debt (Recent Filing)$169.54M
Price to Earnings (P/E)17.7
Beta0.84
Next Earnings
Aug 05, 2026EPS Estimate
0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.12
Shares Outstanding251,355,090
10 Day Avg. Volume1,091
30 Day Avg. Volume2,207
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)5.48
Price to Sales (P/S)5.10
P/FCF Ratio14.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$51.64Price Target Upside15.08% Upside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)3.5
Revenue Forecast (FY)$2.60B
Bulls Say, Bears Say
Bulls Say
High Profitability & MarginsSustained, very high margins indicate structural pricing power and low COGS for its small‑molecule portfolio. Durable profitability supports reinvestment in R&D, continued capital returns and resilience through revenue cycles, improving long‑term free cash flow conversion.
Strong Cash Generation & Low LeverageConsistent high operating and free cash flow plus a large cash balance and minimal leverage give durable financial flexibility. This enables funding of pivotal trials, buybacks, and partnerships without reliance on dilutive or costly external financing over the medium term.
Commercial Momentum & Pipeline ProgressDouble‑digit prescription growth and rising market share demonstrate sustainable commercial execution of the cabo franchise. Concurrent ZANZA regulatory progress and multiple pivotal STELLAR trials diversify future revenue streams and indicate a credible path to franchise expansion beyond cabo.
Bears Say
Rising Gross‑to‑Net DeductionsStructural increases in 340B volumes, Medicare Part D discounts and co‑pay assistance compress net realized revenue per unit. Persistently higher gross‑to‑net reduces durable top‑line conversion and can erode long‑run margins absent offsetting price or mix improvements.
Revenue Concentration & LumpinessHeavy reliance on a single franchise and milestone/timing‑sensitive collaboration income increases structural volatility in revenues and cash flow. This concentration makes long‑term growth dependent on sustaining cabo sales and limits diversification until new assets reach commercial scale.
Pipeline & Regulatory Timing RiskFuture growth materially depends on several timing‑sensitive pivotal trials and regulatory outcomes. Delays, immature endpoints, or negative readouts would materially affect long‑term revenue trajectories, making the company’s durable prospects contingent on successful late‑stage execution.
Exelixis News
0IJO FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest share price was $33.81 and its highest was $57.49 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $13.92B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Aug 05, 2026 which is in 9 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on May 05, 2026. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.762 by $0.108.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Exelixis dividends here
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.85.
How many shares outstanding does Exelixis have?
Exelixis has 251,355,090 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.87 in its last earnings report, beating expectations of $0.762. Following the earnings report the stock price went up 8.305%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in GB:0IJO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$51.64 (15.08% Upside)
$51.64 (15.08% Upside)
Blogger Sentiment
Bullish
GB:0IJO Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $11.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.59%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
0IJO Company Deck
0IJO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for CABOMETYX (double-digit global growth, notable TRx and market share gains), solid profitability and cash position, active share repurchases, and substantial advancement of ZANZA with one positive pivotal result (20% OS risk reduction in STELLAR-303 ITT) and multiple ongoing pivotal trials across tumor types. Offsetting these positives were increased gross-to-net deductions (30.2%), a materially higher tax provision, reliance on several upcoming readouts (some immature or timing‑sensitive), and broader development complexity highlighted by a competitive miss in a related triplet program. On balance, operational and commercial strengths and a broad, advancing pipeline materially outweigh the near-term execution and regulatory uncertainties.View all GB:0IJO earnings summaries0IJO Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
0IJO Stock 12 Month Forecast
Average Price Target
$51.64
▲(15.08% Upside)